High interest in a long-acting injectable formulation of pre-exposure prophylaxis for HIV in young men who have sex with men in NYC: a P18 cohort substudy.

In the context of continued high rates of condomless anal intercourse and HIV-1 infection, young men who have sex with men (YMSM) need additional effective and desirable HIV prevention tools. This study reports on the willingness of a racially-ethnically diverse cohort of YMSM to use a new biomedica...

Full description

Bibliographic Details
Main Authors: Kathrine Meyers, Kristina Rodriguez, Robert W Moeller, Ilana Gratch, Martin Markowitz, Perry N Halkitis
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2014-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC4263701?pdf=render
id doaj-960ca8684cb64c9fa31970d0bb8d511e
record_format Article
spelling doaj-960ca8684cb64c9fa31970d0bb8d511e2020-11-25T00:43:58ZengPublic Library of Science (PLoS)PLoS ONE1932-62032014-01-01912e11470010.1371/journal.pone.0114700High interest in a long-acting injectable formulation of pre-exposure prophylaxis for HIV in young men who have sex with men in NYC: a P18 cohort substudy.Kathrine MeyersKristina RodriguezRobert W MoellerIlana GratchMartin MarkowitzPerry N HalkitisIn the context of continued high rates of condomless anal intercourse and HIV-1 infection, young men who have sex with men (YMSM) need additional effective and desirable HIV prevention tools. This study reports on the willingness of a racially-ethnically diverse cohort of YMSM to use a new biomedical prevention approach, a long-acting injectable pre-exposure prophylaxis (LAI-PrEP) agent.A cross-sectional study conducted between June-August 2013 recruited participants from an ongoing cohort study of YMSM in NYC. Participants included 197 YMSM, of whom 72.6% (n = 143) identified as men of color. Two outcomes were measured through computer-assisted self-interviews: 1) willingness to use long-acting injectable PrEP and 2) preference for route of administration of PrEP. In addition, concerns about perceived impacts of PrEP on health and risk behavior, access to health services, and stigma were investigated.Over 80% (n = 159/197, p<0.001) of participants stated they would be willing to use LAI-PrEP. With regards to preference for mode of delivery 79.2% (n = 156/197, p<0.001) stated they would prefer an injection administered every three months over a daily pill or neither one.This study is the first to explore acceptability of LAI-PrEP in the US. A significant majority of participants expressed willingness to use LAI and the majority preferred LAI-PrEP. LAI-PrEP holds great promise in that it could circumvent the adherence challenges associated with daily dosing, especially if nested within appropriate psycho-behavioral support. Medical providers whose patients include YMSM at high risk for HIV infection should note the positive attitudes toward PrEP, and specifically LAI-PrEP.http://europepmc.org/articles/PMC4263701?pdf=render
collection DOAJ
language English
format Article
sources DOAJ
author Kathrine Meyers
Kristina Rodriguez
Robert W Moeller
Ilana Gratch
Martin Markowitz
Perry N Halkitis
spellingShingle Kathrine Meyers
Kristina Rodriguez
Robert W Moeller
Ilana Gratch
Martin Markowitz
Perry N Halkitis
High interest in a long-acting injectable formulation of pre-exposure prophylaxis for HIV in young men who have sex with men in NYC: a P18 cohort substudy.
PLoS ONE
author_facet Kathrine Meyers
Kristina Rodriguez
Robert W Moeller
Ilana Gratch
Martin Markowitz
Perry N Halkitis
author_sort Kathrine Meyers
title High interest in a long-acting injectable formulation of pre-exposure prophylaxis for HIV in young men who have sex with men in NYC: a P18 cohort substudy.
title_short High interest in a long-acting injectable formulation of pre-exposure prophylaxis for HIV in young men who have sex with men in NYC: a P18 cohort substudy.
title_full High interest in a long-acting injectable formulation of pre-exposure prophylaxis for HIV in young men who have sex with men in NYC: a P18 cohort substudy.
title_fullStr High interest in a long-acting injectable formulation of pre-exposure prophylaxis for HIV in young men who have sex with men in NYC: a P18 cohort substudy.
title_full_unstemmed High interest in a long-acting injectable formulation of pre-exposure prophylaxis for HIV in young men who have sex with men in NYC: a P18 cohort substudy.
title_sort high interest in a long-acting injectable formulation of pre-exposure prophylaxis for hiv in young men who have sex with men in nyc: a p18 cohort substudy.
publisher Public Library of Science (PLoS)
series PLoS ONE
issn 1932-6203
publishDate 2014-01-01
description In the context of continued high rates of condomless anal intercourse and HIV-1 infection, young men who have sex with men (YMSM) need additional effective and desirable HIV prevention tools. This study reports on the willingness of a racially-ethnically diverse cohort of YMSM to use a new biomedical prevention approach, a long-acting injectable pre-exposure prophylaxis (LAI-PrEP) agent.A cross-sectional study conducted between June-August 2013 recruited participants from an ongoing cohort study of YMSM in NYC. Participants included 197 YMSM, of whom 72.6% (n = 143) identified as men of color. Two outcomes were measured through computer-assisted self-interviews: 1) willingness to use long-acting injectable PrEP and 2) preference for route of administration of PrEP. In addition, concerns about perceived impacts of PrEP on health and risk behavior, access to health services, and stigma were investigated.Over 80% (n = 159/197, p<0.001) of participants stated they would be willing to use LAI-PrEP. With regards to preference for mode of delivery 79.2% (n = 156/197, p<0.001) stated they would prefer an injection administered every three months over a daily pill or neither one.This study is the first to explore acceptability of LAI-PrEP in the US. A significant majority of participants expressed willingness to use LAI and the majority preferred LAI-PrEP. LAI-PrEP holds great promise in that it could circumvent the adherence challenges associated with daily dosing, especially if nested within appropriate psycho-behavioral support. Medical providers whose patients include YMSM at high risk for HIV infection should note the positive attitudes toward PrEP, and specifically LAI-PrEP.
url http://europepmc.org/articles/PMC4263701?pdf=render
work_keys_str_mv AT kathrinemeyers highinterestinalongactinginjectableformulationofpreexposureprophylaxisforhivinyoungmenwhohavesexwithmeninnycap18cohortsubstudy
AT kristinarodriguez highinterestinalongactinginjectableformulationofpreexposureprophylaxisforhivinyoungmenwhohavesexwithmeninnycap18cohortsubstudy
AT robertwmoeller highinterestinalongactinginjectableformulationofpreexposureprophylaxisforhivinyoungmenwhohavesexwithmeninnycap18cohortsubstudy
AT ilanagratch highinterestinalongactinginjectableformulationofpreexposureprophylaxisforhivinyoungmenwhohavesexwithmeninnycap18cohortsubstudy
AT martinmarkowitz highinterestinalongactinginjectableformulationofpreexposureprophylaxisforhivinyoungmenwhohavesexwithmeninnycap18cohortsubstudy
AT perrynhalkitis highinterestinalongactinginjectableformulationofpreexposureprophylaxisforhivinyoungmenwhohavesexwithmeninnycap18cohortsubstudy
_version_ 1725277303932452864